NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

Johnson & Johnson Reports Q4 and Full-Year 2022 Results

by Ed Johnson
January 25, 2023
A A

2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%*

2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*

2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%*

2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*

Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”

OVERALL FINANCIAL RESULTS

Q4Full Year
($ in Millions, except EPS)20222021% Change20222021%  Change
Reported Sales$23,706$24,804(4.4)%$94,943$93,7751.3%
Net Earnings$3,520$4,736(25.7)%$17,941$20,878(14.1)%
EPS (diluted)$1.33$1.77(24.9)%$6.73$7.81(13.8)%
       
Q4Full Year
Non-GAAP* ($ in Millions, except EPS)20222021%  Change20222021%  Change
Operational Sales1,20.9%6.1%
Adjusted Operational Sales1,30.8%6.2%
Adjusted Net Earnings1,4$6,218$5,6789.5%$27,038$26,1953.2%
Adjusted EPS (diluted)1,4$2.35$2.1310.3%$10.15$9.803.6%

 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

  2 Excludes the impact of translational currency

  3 Excludes the net impact of acquisitions and divestitures and translational currency

  4 Excludes intangible amortization expense and special items

Note: values may have been rounded

REGIONAL SALES RESULTS

Q4% Change
($ in Millions)20222021ReportedOperational1,2CurrencyAdjusted Operational1,3
U.S.$12,516$12,1632.9%2.9–2.7
International11,19012,641(11.5) (1.1)(10.4)(1.0)
Worldwide$23,706$24,804(4.4)%0.9(5.3)0.8
Full Year% Change
($ in Millions)20222021ReportedOperational1,2CurrencyAdjusted Operational1,3
U.S.$48,580$47,1563.0%3.0–3.0
International46,36346,619(0.6)%9.1(9.7)9.3
Worldwide$94,943$93,7751.3%6.1(4.8)6.2

 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

 2 Excludes the impact of translational currency

 3 Excludes the net impact of acquisitions and divestitures and translational currency

Note: Values may have been rounded

SEGMENT SALES RESULTS

Q4% Change 
($ in Millions)20222021ReportedOperational1,2CurrencyAdjusted Operational1,3 
Consumer Health4$3,767$3,7281.0%6.4(5.4)6.4
Pharmaceutical413,16314,217(7.4) (2.5)(4.9)(2.3)
MedTech6,7766,859(1.2) 4.9(6.1)4.4
Worldwide$23,706$24,804(4.4)%0.9(5.3)0.8
Full Year% Change
($ in Millions)20222021ReportedOperational1,2CurrencyAdjusted Operational1,3
Consumer Health4$14,953$15,035(0.5)%3.6(4.1)3.9
Pharmaceutical452,56351,6801.7  6.7(5.0)6.8
MedTech27,42727,0601.4  6.2(4.8)6.1
Worldwide$94,943$93,7751.3%6.1(4.8)6.2

  1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

  2 Excludes the impact of translational currency

  3 Excludes the net impact of acquisitions and divestitures and translational currency

  4 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

Note: Values may have been rounded

Tags: < Financial Results
ShareTweetShareSend

Related Industries

Healthcare

BD Names Dr. Ronald Silverman as Chief Medical Officer

November 22, 2023
Healthcare

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023

November 20, 2023
Healthcare

Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.

November 18, 2023
Healthcare

3M Reveals Solventum as New Name for Planned, Independent Health Care Company Following Spin-Off

November 17, 2023
Healthcare

Merck Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District

November 15, 2023
Healthcare

Bayer and Recursion focus research collaboration on Oncology

November 10, 2023

Guidehouse, Leading Global Provider of Consulting Services, to be Acquired by Bain Capital Private Equity

November 7, 2023

...

Otis Named one of the World’s Top Companies for Women by Forbes

October 31, 2023

...

ExxonMobil starts production at third offshore Guyana project

November 15, 2023

...

Cargill’s newly expanded soybean processing plant in Sidney, Ohio poised to connect local farmers to growing demand for soybean oil and meal

November 2, 2023

...

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023

November 20, 2023

...

Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024

November 1, 2023

...

UPS Completes Acquisition of MNX Global Logistics

November 7, 2023

...

Mary Kay Inc. Announces Partnership with Global Shea Alliance to Promote Sustainability and Women’s Empowerment

November 22, 2023

...

Weather-Related Natural Disasters Likely To Have Material Impact On Sustainability Initiatives, Says Honeywell’s Environmental Sustainability Index

November 2, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NORTH AMERICAN BUSINESS All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NORTH AMERICAN BUSINESS All rights reserved.